

## Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM)

### Measure Description

The percentage of children or adolescents 1-17 years of age who had two or more antipsychotic prescriptions and had metabolic testing. Three rates are reported:

1. The percentage of children and adolescents on antipsychotics who received blood glucose testing.
2. The percentage of children and adolescents on antipsychotics who received cholesterol testing.
3. The percentage of children and adolescents on antipsychotics who received blood glucose and cholesterol testing.

### Required Exclusions

- Members in hospice or using hospice services any time during the measurement year.
- Members who died any time during the measurement year.

### Codes Included in the Current HEDIS® Measure

#### Codes to Identify Diabetes Screening and Cholesterol Screening

Description	Code
Diabetes Glucose Tests	CPT: 80047, 80048, 80050, 80053, 80069, 82947, 82950, 82951
Diabetes HbA1c Test & Lab Results	CPT: 83036, 83037 CPT II: 3044F (<7%); 3046F (>9%); 3051F (≥7% and <8%); 3052F (≥8% and <9%)
Cholesterol Tests	CPT: 82465, 83718, 83722, 84478
Cholesterol LDL-C Test & Lab Results	CPT: 80061, 83700, 83701, 83704, 83721 CPT II: 3048F (<100 gm/dL); 3049F (100-129 mg/dL); 3050F (≥130 mg/dL)

### Medications

#### Antipsychotic Medications

Description	Prescription
Miscellaneous Antipsychotic Agents	Aripiprazole, Asenapine, Brexpiprazole, Cariprazine, Clozapine, Haloperidol, lloperidone, Loxapine, Lurasidone, Molindone, Olanzapine, Paliperidone, Pimozide, Quetiapine, Risperidone, Ziprasidone
Phenothiazine Antipsychotics	Chlorpromazine, Fluphenazine, Perphenazine, Thioridazine, Trifluoperazine
Thioxanthenes	Thiothixene
Long-Acting Injections	Aripiprazole, Aripiprazole lauroxil, Fluphenazine decanoate, Haloperidol decanoate, Olanzapine, Paliperidone palmitate, Risperidone

#### Antipsychotic Combination Medications

Description	Prescription
Psychotherapeutic Combinations	Fluoxetine-olanzapine, Perphenazine-amitriptyline

Please submit a request for coverage when prescribing Psychotherapeutic Combination medications.

#### Prochlorperazine Medications

Description	Prescription
Phenothiazine Antipsychotics	Prochlorperazine

## Ways to Improve HEDIS® Scores

- Monitoring children on antipsychotic medications helps to avoid metabolic health complications such as weight gain and diabetes.
- Educate parents/guardians about the signs of metabolic disturbances, including long term consequences of pediatric and adolescence obesity and poor cardiometabolic outcomes in adulthood.
- Establish a baseline and continuously monitor metabolic indices to ensure appropriate management of side-effects of antipsychotic medication therapy.
- Explore partnering with key community and school-based organizations focused on child/adolescent health to provide education about healthy diet, nutrition and exercise.
- Consider prescribing long-acting injectable medications for non-compliance issues.
- Schedule follow-up appointments after the second anti-psychotic prescription and metabolic lab tests.

All summaries of the measures contained herein are reproduced with permission from HEDIS® Volume 2: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA).

The information presented herein is for informational and illustrative purposes only. It is not intended, nor is it to be used, to define a standard of care or otherwise substitute for informed medical evaluation, diagnosis and treatment which can be performed by a qualified medical professional. Passport by Molina Healthcare does not warrant or represent that the information contained herein is accurate or free from defects.

### **COPYRIGHT NOTICE AND DISCLAIMER**

HEDIS® is a registered trademark of the National Committee for Quality Assurance (“NCQA”). The HEDIS measures and specifications were developed by and are owned by NCQA. NCQA holds a copyright in these materials and may rescind or alter these materials at any time. Users of the HEDIS measures and specifications shall not have the right to alter, enhance or otherwise modify the HEDIS measures and specifications, and shall not disassemble, recompile or reverse engineer the HEDIS measures and specifications. Anyone desiring to use or reproduce the materials, subject to licensed user restrictions, without modification for an internal non-commercial purpose may do so without obtaining any approval from NCQA. Use of the Rules for Allowable Adjustments of HEDIS to make permitted adjustments of the materials does not constitute a modification. All other uses, including a commercial use (including but not limited to vendors using the measures and specifications with a product or service to calculate measure results), or any external reproduction, distribution and publication of the HEDIS measures or results (“rates”) therefrom must be approved by NCQA and are subject to a license at the discretion of NCQA. Any use of the materials to identify records or calculate measure results, for example, requires a custom license and may necessitate certification pursuant to NCQA’s Measure Certification Program.

HEDIS measures and specifications are not clinical guidelines, do not establish a standard of medical care and have not been tested for all potential applications. The measures and specifications are provided “as is” without warranty of any kind. NCQA makes no representations, warranties or endorsements about the quality of any product, test or protocol identified as numerator compliant or otherwise identified as meeting the requirements of a HEDIS measure or specification. NCQA also makes no representations, warranties or endorsements about the quality of any organization or clinician who uses or reports performance measures. NCQA has no liability to anyone who relies on HEDIS measures and specifications or data reflective of performance under such measures and specifications.

Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. NCQA disclaims all liability for use or accuracy of any coding contained in the specifications.

The American Medical Association holds a copyright to the CPT® codes contained in the measure specifications.

The American Hospital Association holds a copyright to the Uniform Billing Codes (“UB”) contained in the measure specifications. The UB Codes in the HEDIS specifications are included with the permission of the AHA. All uses of the UB Codes may require a license from the AHA. Specifically, anyone desiring to use the UB Codes in a commercial product to generate HEDIS results, or for any other commercial use, must obtain a commercial use license directly from the AHA. To inquire about licensing, contact [ub04@aha.org](mailto:ub04@aha.org).

Reprinted with permission by NCQA. ©2022 by the National Committee for Quality Assurance.  
All rights reserved.